Blackstone-Led $1.3 Billion Financing Fuels Paratek and Radius Health Merger
A significant $1.3 billion financing package led by Blackstone Credit &. Insurance (BXCI) has finalized the combination of Paratek Pharmaceuticals and Radius Health, creating a larger, more diversified specialty pharmaceutical company. The deal, announced on March 18, 2026, positions the newly merged entity for substantial growth, with projected revenues nearing $1 billion in 2026.
The Strategic Rationale Behind the Combination
The merger brings together Paratek’s existing portfolio – including NUZYRA® (omadacycline) for bacterial infections, and XHANCE® (fluticasone propionate) – with Radius Health’s TYMLOS® (abaloparatide), an osteoporosis therapy. This diversification is a key element of the strategy, backed by B-FLEXION Life Sciences, to build a robust pharmaceutical platform focused on targeted therapeutic areas.
According to Jonathan Brayman, Managing Director at BXCI, the financing reflects their ability to provide “large-scale capital solutions to life sciences companies.” The combined company aims to leverage disciplined commercial execution, lifecycle management, and clinical development to maximize the potential of its assets.
Blackstone’s Growing Role in the Pharmaceutical Sector
This investment underscores Blackstone’s increasing activity in the pharmaceutical and healthcare sectors. BXCI’s capabilities span a wide range of credit markets, including direct lending, which is particularly relevant for funding complex transactions like this one. The firm’s involvement signals confidence in the long-term prospects of the specialty pharmaceutical market.
B-FLEXION’s Vision for a Scaled Platform
B-FLEXION Life Sciences, a key backer of both Paratek and Radius Health, views the combination as a transformative step. Peter Agnes, Operating Partner at B-Flexion, highlighted the partnership with Blackstone as crucial for the next phase of growth, emphasizing the potential to better serve patients across a wider range of therapeutic areas.
Impact on the Osteoporosis Treatment Landscape
The addition of TYMLOS® to Paratek’s portfolio is particularly noteworthy. Osteoporosis remains a significant public health concern, and innovative therapies like TYMLOS® are crucial for addressing the needs of patients at high risk of fractures. The expanded commercial reach of the combined company could improve access to this important treatment.
Financing Details and BioPharma Credit’s Role
The $1.3 billion financing included contributions from multiple sources, including debt financing from funds managed by Blackstone Credit & Insurance, as well as BioPharma Credit PLC. BioPharma Credit replaced a previous $25 million investment with the modern financing, receiving $27 million in return, including principal and prepayment fees.
Frequently Asked Questions
What is Blackstone Credit & Insurance?
Blackstone Credit & Insurance is a leading credit investor providing capital solutions to companies across various sectors, including healthcare and pharmaceuticals.
What are the key products in Paratek’s portfolio?
Paratek’s key products include NUZYRA® (omadacycline) and XHANCE® (fluticasone propionate), with TYMLOS® (abaloparatide) added through the Radius Health combination.
What is B-FLEXION Life Sciences’ role in this deal?
B-FLEXION Life Sciences is an investment manager and a key backer of both Paratek and Radius Health, driving the strategic vision for the combined company.
What is the projected revenue for the combined company in 2026?
The combined company is expected to generate nearly $1 billion in revenue in 2026.
Where can I find more information about Paratek Pharmaceuticals?
You can visit Paratek’s website or follow them on LinkedIn and X.
Did you know? Blackstone’s involvement in this deal highlights the growing trend of private credit firms playing a larger role in financing pharmaceutical mergers and acquisitions.
Pro Tip: Maintain an eye on the development of TYMLOS® as the combined company expands its commercial reach – this could be a key growth driver in the osteoporosis treatment market.
Stay informed about the latest developments in the pharmaceutical industry. Explore more articles on our site or subscribe to our newsletter for regular updates.
